Study unveils a role of mitochondria in dietary fat processing
The maintenance of a balanced lipid homeostasis is critical for our health. While consumption of excessive amounts of fatty foods contributes to metabolic diseases such as obesity and atherosclerosis, fat is an indispensable component of our diet. Digested lipids supply the body with essential building blocks and facilitate the absorption of important vitamins. In a […]
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
SEOUL, South Korea — Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from the SIENDO trial. The updated, long-term data from the phase III study showed that, at a median follow-up of 25.3 months, median PFS was 27.4 […]
Could Cetuximab Maintenance Play a Role in RAS Wild-Type Metastatic CRC?
Maintenance therapy with cetuximab (Erbitux) after FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus cetuximab induction therapy led to better outcomes for patients with RAS wild-type metastatic colorectal cancer (CRC) in a phase II randomized trial, yet it failed to reach the study’s prespecified threshold for success. At 6 months after randomization, more patients assigned to maintenance […]
CDC: Dialysis Patients Carry Heavier COVID Burden
Patients on maintenance dialysis had somewhat higher rates of SARS-CoV-2 infections and related deaths than seen in the general U.S. population, although immunization mitigated some of the excess risk, the CDC reported. From June 30, 2021, to Sept. 27, 2022, the overall infection rate per 10,000 patient-weeks was 30.47 among maintenance dialysis patients, with a […]
Generic Fluticasone–Salmeterol Inhaler for COPD Matches Branded Product
A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched cohort study found. With approximately 3 months of routine use, the generic form of the inhaled corticosteroid and long-acting beta-agonist (ICS-LABA) inhaler was shown to carry a similar incidence of first moderate-to-severe […]
OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancer
For women with platinum-sensitive recurrent ovarian cancer, maintenance therapy using an individualized starting dose of niraparib (Zejula) did not improve overall survival (OS) despite producing a statistically and clinically significant progression-free survival (PFS) benefit in the phase III NORA study. An interim analysis of the key secondary endpoint showed a median OS of 46.3 months […]
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) annual congress. At 7 years in the SOLO-1 trial, 67% of patients with advanced BRCA-mutated ovarian cancer treated with the […]
Chemo-Free Maintenance Combo Promising in Pancreatic Cancer
Pairing a PARP inhibitor and immune checkpoint inhibitor together may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma (PDAC), according to findings of a single-center phase Ib/II study. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib (Zejula) with the anti CTLA-4 antibody ipilimumab (Yervoy) achieved […]